Active Biotech AB Interim Report January – June 2011

Aug 11, 2011 08:30 (CEST) 
· Laquinimod - results of Phase III BRAVO trial reinforce unique profile of
laquinimod for multiple sclerosis treatment

· TASQ - recruitment of patients for the Phase III trial ongoing

· TASQ - partnership agreement initiated with Ipsen

· ANYARA - Phase III trial continues according to plan

· 57-57 - preparation for the start of the SSC exploratory clinical trial in
progress

· ISI - project is proceeding as planned

· RhuDex(TM) - preparations for continued clinical development in progress

· Net sales SEK 228.8 M (6.1)

· Operating profit SEK 70.6 M  (loss: 102,4)

· Profit after tax SEK 77.7 M (loss: 108.3)

· Earnings per share for the period amounted to SEK 1.14 (loss: 1.67)


For further information, please contact:

Tomas Leanderson
President and CEO
Tel: +46 (0)46-19 20 95

Hans Kolam
CFO
Tel: +46 (0)46-19 20 44


Active Biotech AB
(Corp. Reg. No: 556223-9227)
PO Box 724, SE-220 07 Lund
Tel: +46 (0)46-19 20 00
Fax: +46 (0)46-19 11 00

This report is also available at www.activebiotech.com




Active Biotech AB Interim Report January – June 2011:
http://hugin.info/1002/R/1537777/469595pdf




This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
    other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
     originality of the information contained therein.

Source: Active Biotech via Thomson Reuters ONE

[HUG#1537777]